Bristol Myers Squibb reports preliminary Phase 3 ADEPT-1 and ADEPT-3 findings for KarXT, showing improvements in Alzheimer’s disease-associated psychosis.
Written By: Saniya Katakdhond, PharmD
Reviewed By: Pharmacally Editorial Team
Bristol Myers Squibb (BMS) has reported the first clinical findings from its Phase 3 ADEPT program evaluating xanomeline and trospium chloride (KarXT) in patients with psychosis associated with Alzheimer’s disease. Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference on November 18, 2026, the preliminary findings include data from the 12-week open-label lead-in period of ADEPT-1 and the 52-week open-label extension study ADEPT-3.
Both studies showed reductions in clinician-assessed hallucination and delusion scores and overall disease severity following KarXT treatment. The findings also indicated generally favorable tolerability, with no new safety signals identified. However, these results are based on descriptive analyses of open-label treatment periods, while the double-blind treatment-period data across the ADEPT program remain blinded.
Clinical Need in Alzheimer’s Disease-Associated Psychosis
Approximately 30–50% of patients with Alzheimer’s disease experience psychosis symptoms, including hallucinations and delusions, during the course of their illness. These symptoms are associated with greater caregiver burden, accelerated cognitive and functional decline, and increased rates of institutionalization and mortality.
Currently, there are no FDA-approved treatments specifically indicated for psychosis associated with Alzheimer’s disease. Clinical management frequently relies on off-label antipsychotics, which carry an FDA Boxed Warning regarding increased mortality in older adults with dementia-related psychosis. FDA labeling also identifies cerebrovascular risks, including stroke, in this population.
ADEPT-1: Improvements Observed During 12-Week Open-Label Treatment
ADEPT-1 (NCT05511363) is a global Phase 3, randomized, double-blind, placebo-controlled relapse-prevention study evaluating KarXT in adults with Alzheimer’s disease-associated psychosis. Its design comprises a 12-week open-label treatment period followed by a 26-week randomized withdrawal period, with time to relapse serving as the primary endpoint during the double-blind phase.
Among 320 participants enrolled at the time of analysis, 273 (85.3%) completed the 12-week open-label period. Improvements from baseline were observed across two clinical measures:
- Neuropsychiatric Inventory-Clinician Hallucinations and Delusions (NPI-C H+D): Mean reduction of 12.0 points from a baseline score of 14.4 (n=266).
- Clinical Global Impression-Severity (CGI-S): Mean reduction of 1.9 points from a baseline score of 4.5 (n=267).
Treatment-emergent adverse events (TEAEs) occurred in 56.6% of participants. Serious TEAEs were reported in 5.0%, while 4.4% experienced TEAEs leading to treatment discontinuation.
ADEPT-3: 52-Week Long-Term Safety and Tolerability Findings
ADEPT-3 (NCT05980949) is a global Phase 3, 52-week open-label extension study enrolling participants who completed ADEPT-1, ADEPT-2 or ADEPT-4. Its primary objective is to evaluate the long-term safety and tolerability of KarXT in adults with Alzheimer’s disease-associated psychosis.
Among 401 participants enrolled at the time of analysis, 273 (68.1%) completed the 52-week treatment period. TEAEs occurred in 65.1% of participants, serious TEAEs in 7.7%, and TEAEs leading to treatment discontinuation in 4.7%.
Improvements in clinical scores were also observed from the ADEPT-3 open-label baseline among evaluable participants:
NPI-C H+D: Mean reduction of 5.1 points from a baseline score of 8.9 (n=270).
- CGI-S: Mean reduction of 0.8 points from a baseline score of 3.4 (n=277).
Although these findings provide preliminary information on longer-term exposure, the 68.1% completion rate and open-label design warrant cautious interpretation.
Understanding KarXT’s Mechanism of Action
KarXT combines xanomeline, a central M1- and M4-preferring muscarinic receptor agonist, with trospium chloride, a muscarinic receptor antagonist designed to reduce peripheral cholinergic side effects. Through central cholinergic muscarinic receptor modulation, the combination is designed to engage molecular pathways involved in behavior and cognition.
KarXT is FDA-approved under the brand name Cobenfy in the United States for schizophrenia in adults. Its use in Alzheimer’s disease-associated psychosis remains investigational.
The Road Ahead: Awaiting Blinded Phase 3 Results
The broader ADEPT program also includes ADEPT-2 (NCT06126224) and ADEPT-4 (NCT06585787), which evaluate the acute efficacy of KarXT, and ADEPT-5 (NCT06947941), which investigates twice-daily dosing in this patient population.
An important upcoming milestone is the 26-week double-blind randomized withdrawal period of ADEPT-1, designed to assess time to relapse as its primary endpoint. Results from this controlled phase, alongside the acute efficacy findings from ADEPT-2 and ADEPT-4, will be essential in determining whether the symptom reductions observed during open-label treatment translate into a demonstrable treatment benefit under controlled conditions.
Clinical Interpretation
The preliminary ADEPT findings provide an encouraging initial clinical assessment of KarXT in Alzheimer’s disease-associated psychosis, an indication characterized by substantial unmet medical need. The observed reductions in NPI-C H+D and CGI-S scores indicate improvements in clinician-assessed symptoms during both short-term and extended open-label treatment, while ADEPT-3 provides preliminary information on longer-term safety and tolerability.
Nevertheless, neither dataset independently establishes clinical efficacy. Both analyses were conducted during open-label treatment without a concurrent placebo control. Participants who completed or prematurely discontinued the respective open-label periods were included in the analyses, whereas those still receiving treatment at the data cutoff were excluded. Consequently, the observed score reductions cannot establish comparative treatment benefit.
The forthcoming double-blind results, particularly the randomized withdrawal assessment in ADEPT-1 and the acute efficacy findings from ADEPT-2 and ADEPT-4, will be critical in determining KarXT’s therapeutic potential for Alzheimer’s disease-associated psychosis.
Reference
Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease, Bristol Myers Squibb, 18 November 2026
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated with Alzheimer’s Disease (ADEPT-1), ClinicalTrials.gov ID NCT05511363
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimer’s Disease (ADEPT-3), ClinicalTrials.gov ID NCT05980949
About the Writer
Saniya Sanjay Katakdhond (Linkedin) is a Doctor of Pharmacy professional with hands-on experience in patient case review, clinical documentation, medical record analysis, and patient care.
Her hospital experience has strengthened her understanding of clinical conditions, treatment approaches, and multidisciplinary healthcare practices.
With ICH-GCP certification and a research-oriented approach, she brings clinical insight and attention to detail to healthcare content development.
As a healthcare writer, Saniya focuses on translating clinical knowledge and patient-care experience into clear, accurate, and evidence-informed medical content.
